Physician profile
Emily Cherry
NPI 1407359524
$1,295.15
in general payments reported to CMS, 2019-2025
23 companies · $1,199 in 2025
The $1,199 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $95.85 · 2025: $1,199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,099 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,099.31 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $266.66 | 2022-2025 | Keytruda, Keytruda Qlex, Welireg |
| Geron Corporation | $135.36 | 2025 | Rytelo |
| Astrazeneca Pharmaceuticals LP | $114.02 | 2025 | Imfinzi |
| Seagen INC. | $99.99 | 2025 | |
| Celgene Corporation | $78.11 | 2025 | Reblozyl |
| Takeda Pharmaceuticals U.S.A., INC. | $74.15 | 2025 | Fruzaqla |
| Novartis Pharmaceuticals Corporation | $62.28 | 2025 | |
| Daiichi Sankyo INC. | $60.59 | 2025 | Enhertu, Vanflyta |
| Janssen Biotech, INC. | $58.49 | 2025 | Rybrevant, Talvey |
| Gilead Sciences, INC. | $52.92 | 2025 | Trodelvy |
| Genmab U.S., INC. | $47.52 | 2025 | Epkinly |
| Incyte Corporation | $32.62 | 2025 | Zynyz, Pemazyre, Monjuvi |
| Tersera Therapeutics LLC | $30.16 | 2025 | Zoladex |
| E.R. Squibb & Sons, L.L.C. | $23.87 | 2025 | Opdivo |
| Recordati_rare_diseases_inc. | $21.93 | 2025 | Enjaymo |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acrotech Biopharma INC. | $21.62 | 2025 | Beleodaq |
| Taiho Oncology, INC. | $18.00 | 2025 | |
| Astellas Pharma US INC | $17.72 | 2025 | Padcev |
| Pharmaessentia USA Corporation | $17.34 | 2025 | Besremi |
| Beone Medicines USA, INC. | $17.13 | 2025 | Tevimbra |
| Emd Serono, INC. | $16.54 | 2025 | |
| Pfizer INC. | $14.42 | 2025 | |
| Jazz Pharmaceuticals INC. | $13.71 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Cherry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.